Author Affiliation: Istituto Neurologico Carlo Besta, Università Cattolica del Sacro Cuore, Milano, Italy.
The market for botulinum neurotoxins is becoming as crowded in the United States as in Europe. Last year, following approval of a second type A botulinum neurotoxins, the US Food and Drug Administration announced generic (or nonproprietary) name changes for all of the versions of injectable botulinum neurotoxins, and added a boxed warning on the labels of these potential biological weapons to describe the spread of the toxin and the attendant, possibly life-threatening effects.1
Albanese A. Terminology for Preparations of Botulinum NeurotoxinsWhat a Difference a Name Makes. JAMA. 2011;305(1):89-90. doi:10.1001/jama.2010.1937